chemistry_totojang1977
Shutterstock.com/totojang1977
15 July 2021PharmaSophie Topham

UK experimental use exemptions: part 1—the original

Section 60(1) of the Patents Act 1977 (UKPA) provides that use in the UK of a product or process falling within the scope of the claims of a granted patent, without the consent of the proprietor, is an infringement of those claims. However, Section 60 also provides that in certain circumstances, including, and of particular relevance to the life sciences sector, experimental uses of the invention—permitted acts that would otherwise constitute an infringement.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
22 September 2026   After a run of UK decisions going against major pharma patents on plausibility, Novartis bucked the trend with Entresto. The company’s lead counsel from Bristows explains why and what patentees can take from the ruling.
Pharma
17 September 2026   Bauer Research Foundation has alleged that the CDMO misappropriated its confidential manufacturing know-how related to NO-Cbl, an anticancer drug candidate in the pre-clinical/translational stage of development for potential human use.
Pharma
16 September 2026   A medicine reaching the end of its primary patent term does not necessarily mean the market is open to generics. The complex patent landscape surrounding semaglutide shows how secondary patents covering indications, formulations and manufacturing processes can extend competitive barriers—and why careful freedom-to-operate analysis is critical before launch, says Ana Neves of Inventa.